Skip to NavigationSkip to content

Roche's Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer

Published on 15/02/19 at 11:09am

NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of HER2-positive breast cancer after surgery in patients whose disease has spread to their lymph nodes, offering a new treatment option for around 2,700 UK patients.

The decision was based on data showing that the combination of Perjeta, Herceptin and chemotherapy resulted in an increased proportion of patients who did not see their cancer spread. However, NICE also noted that there was not enough data supplied to support the efficacy of the combination in extending patient survival times, or even that it could it all.

Roche’s revised economic model submitted to NICE placed the cost-effectiveness estimate below £20,000 per quality-adjusted life year (QALY), allowing the organisation to recommend it as a worthy use of NHS resources.

“We’re pleased that we’ve been able to work with the company to address the uncertainties of pertuzumab as a treatment for early HER2-positive breast cancer,” commented Meindert Boysen, Director of the Centre for Health Technology Assessment at NICE. “Their response means that people who have a high risk of their cancer returning now have a new treatment option that could reduce the risk of that happening.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches